Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
McKesson
Mallinckrodt
Baxter
Express Scripts

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR CARMUSTINE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Carmustine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002461 ↗ Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 2 1988-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy to kill more cancer cells. PURPOSE: This phase II trial is studying giving high-dose chemotherapy followed by bone marrow or peripheral stem cell transplantation to see how well it works in treating patients with refractory Hodgkin's disease or non-Hodgkin's lymphoma.
NCT00002461 ↗ Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Completed Albert Einstein College of Medicine of Yeshiva University Phase 2 1988-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy to kill more cancer cells. PURPOSE: This phase II trial is studying giving high-dose chemotherapy followed by bone marrow or peripheral stem cell transplantation to see how well it works in treating patients with refractory Hodgkin's disease or non-Hodgkin's lymphoma.
NCT00002461 ↗ Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Completed Montefiore Medical Center Phase 2 1988-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy to kill more cancer cells. PURPOSE: This phase II trial is studying giving high-dose chemotherapy followed by bone marrow or peripheral stem cell transplantation to see how well it works in treating patients with refractory Hodgkin's disease or non-Hodgkin's lymphoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Carmustine

Condition Name

Condition Name for Carmustine
Intervention Trials
Lymphoma 69
Brain and Central Nervous System Tumors 34
Leukemia 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Carmustine
Intervention Trials
Lymphoma 119
Lymphoma, Non-Hodgkin 53
Glioblastoma 35
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Carmustine

Trials by Country

Trials by Country for Carmustine
Location Trials
United States 852
Canada 58
United Kingdom 25
France 20
Spain 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Carmustine
Location Trials
California 46
Ohio 44
New York 43
Texas 39
Maryland 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Carmustine

Clinical Trial Phase

Clinical Trial Phase for Carmustine
Clinical Trial Phase Trials
Phase 4 1
Phase 3 37
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Carmustine
Clinical Trial Phase Trials
Completed 134
Terminated 26
Unknown status 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Carmustine

Sponsor Name

Sponsor Name for Carmustine
Sponsor Trials
National Cancer Institute (NCI) 112
M.D. Anderson Cancer Center 13
Memorial Sloan Kettering Cancer Center 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Carmustine
Sponsor Trials
Other 284
NIH 121
Industry 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Boehringer Ingelheim
Johnson and Johnson
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.